All Articles

The authors present the results from their study of caregivers’ involvement in treatment decision-making and their need for help in making care decisions as well as communicating with the patient and healthcare team.
Read More

Do administrators really understand the needs of the navigator, and are they fully aware of the infrastructure needed for their navigation programs? In a discussion on administrative engagement in navigation programs at the AONN+ Midyear Conference, Tricia Strusowski, RN, MS, posed these and other provocative questions to attendees.
Read More

New prostate cancer guidelines issued by the National Comprehensive Cancer Network (NCCN) continue to support early detection efforts in well-informed, healthy men while acknowledging that optimal screening of high-risk patients is not completely known. The guidelines also support the use of active surveillance in men who have low-risk prostate cancer.
Read More

HIV status alone should not be used for cancer treatment decision-making, according to the first guidelines from the National Comprehensive Cancer Network (NCCN) on the management of cancer in persons infected with HIV
Read More

The delivery and receipt of cancer care in value-based healthcare models was the subject of a roundtable discussion at the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference.
Read More

Ensuring Consistent and Reliable Biomarker Testing
In the main article of this publication, the current state of programmed-cell death-1 and programmed-cell death ligand-1 (PD-L1) testing, evasion by tumors of the immune system, and the study and use of immune checkpoint inhibitors across multiple tumor types are expertly summarized.
Read More

The Evolving Role of PD-L1 Testing in Patients with Cancer
Clearly, immunotherapy has come of age in multiple tumor types, as described in the main article in this publication. The question now is how to develop more personalized immunotherapy and use biomarkers to identify patients most likely to benefit from this therapy.
Read More

Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology
PD-L1 expression is a rational biomarker to predict response to PD-1/PD-L1 ICI therapy, and has been studied extensively in clinical trials. A recurring theme emerging from available clinical data is that high levels of tumor cell membrane PD-L1 expression correlate with better outcomes with PD-1/PD-L1 blockade.
Read More

The Academy of Oncology Nurse & Patient Navigators (AONN+) is hosting its Annual Conference in Dallas, TX, November 15-18 at the Hilton Anatole. In keeping with the popular slogan—Everything's Bigger in Texas—the Ninth Annual Navigation & Survivorship Conference is going to be huge! More than 1000 nurse and patient navigators are anticipated to come to Dallas and discuss their role in the perpetually evolving oncology care landscape.
Read More

Patient advocacy and community outreach have made the navigation program at Fox Chase Cancer Center a success.
Read More

Page 197 of 281

Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country